What is Windlas Biotech Ltd (WINDLAS) share price return in the past 10 years?

Data is not available for this company

What is the share price of Windlas Biotech Ltd (WINDLAS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Windlas Biotech Ltd (WINDLAS) on 24-Jun-2026 16:59:59 at 16:59 is 863.60.

What is the P/E ratio of Windlas Biotech?

The latest standalone P/E ratio of Windlas Biotech as of 24-Jun-2026 is 26.83.

What is the P/B ratio of Windlas Biotech Ltd (WINDLAS)?

The latest standalone P/B ratio of Windlas Biotech Ltd (WINDLAS) as of 24-Jun-2026 is 3.34.

What is the 52-week high and low of Windlas Biotech Ltd (WINDLAS)?

The 52-week high of Windlas Biotech Ltd (WINDLAS) is Rs. 1095.00 and the 52-week low is Rs. 699.35.

Windlas Biotech Ltd (WINDLAS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Windlas Biotech Ltd (WINDLAS)
Brand: Windlas Biotech

Key Metrics

Valuation Multiples

Market Cap

₹1,782 Cr.

Current Price

₹863.6

52-Week Low / High

₹699 / 1,095

TTM EPS

₹32.2

TTM Sales

₹904 Cr.

Book Value per Share

₹258.7

P/E Ratio

26.83

Higher than its 5-year historical median

Industry PE

48.5

Price to Book (P/B)

3.34

Higher than its 5-year historical median

Price to Sales (P/S)

1.97

Higher than its 5-year historical median

EV/EBITDA

14.78

Higher than its 5-year historical median

Dividend Yield

0.67%

Profitability Efficiency

Return on Equity (ROE)

12.82%

Outperforms industry median

Return on Capital Employed (ROCE)

17.04%

Outperforms industry median

Return on Assets (ROA)

8.75%

Operating Profit Margin

12.4%

Net Profit Margin

7.98%

Gross Profit Margin

14.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

20.43%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

20.51%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

4.32%

Asset Quality

Promoter Holding

61.90%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹524 Cr.

Equity

₹10.3 Cr.

Face Value

₹5

All Time Low / High

₹203.15 / 1197.00

Windlas Biotech stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Windlas Biotech Ltd a good quality company?

Windlas Biotech Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Windlas Biotech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Windlas Biotech Ltd vs industry peers?

Windlas Biotech Ltd revenue CAGR is 18.24%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Windlas Biotech Ltd?

Promoters hold 61.90% of the Windlas Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Windlas Biotech Ltd over the last decade?

Over the last 3 year(s), the stock has delivered a CAGR of 41.51% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	7.7%	9.6%	14.4%	17.9%	14.7%	5.2%	15%	14.4%	18.3%	17%	-
Value Creation Index ⓘ	-0.5	-0.3	0.0	0.3	0.1	-0.6	0.1	0.0	0.3	0.2	-
Growth Parameters ⓘ
Sales ⓘ	274	315	320	288	329	428	466	513	631	760	904
Sales YoY Gr.	-	15.2%	1.6%	-10%	14.1%	30%	9%	10.1%	23%	20.4%	-
Adj EPS ⓘ	2.9	5.8	10.6	12.3	13	15.2	17.5	20	27.9	28.8	32.2
YoY Gr.	-	101.4%	83%	16.5%	5.6%	16.4%	15.8%	13.8%	39.5%	3.5%	-
BVPS (₹) ⓘ	86.8	92.6	103.2	106.6	121	109.3	180.5	191.1	214.2	238.8	258.7
Adj Net Profit ⓘ	4.6	9.2	16.8	22.5	23.7	27.6	38.2	41.8	57.9	60.3	66
Cash Flow from Ops. ⓘ	47.3	6.9	39.1	22.1	24.9	11.5	9	61	109	68.2	-
Debt/CF from Ops. ⓘ	1.1	8.6	1	1.4	1.1	2.7	0.7	0	0	0.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	12%	18.2%	17.7%	20.4%
Adj EPS ⓘ	29.2%	17.2%	18%	3.5%
BVPSⓘ	11.9%	14.6%	9.8%	11.5%
Share Price	-	-	42.1%	-4.9%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	4.4	6.3	10.6	12.4	11.4	13.2	12.9	10.5	13.6	12.6	12.9
Op. Profit Mgn % ⓘ	7.5	7.9	12	15.4	12.6	12.8	11.4	11.7	12.4	12.4	11.6
Net Profit Mgn % ⓘ	1.7	2.9	5.2	7.8	7.2	6.5	8.2	8.1	9.2	7.9	7.4
Debt to Equity ⓘ	0.4	0.4	0.2	0.2	0.1	0.2	0	0	0	0.1	0
Working Cap Days ⓘ	145	115	118	123	126	119	140	171	147	127	116
Cash Conv. Cycle ⓘ	27	9	10	3	22	39	69	68	41	30	58

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	274	315	320	288	329	428	466	513	631	760
Operating Expenses ⓘ +	253	290	282	244	287	373	413	453	553	666
Manufacturing Costs	9	10	11	12	15	34	36	54	53	52
Material Costs	203	234	224	181	212	261	291	299	374	454
Employee Cost	25	29	33	33	44	58	63	70	87	123
Other Costs ⓘ	16	17	14	17	17	19	23	29	38	37
Operating Profit ⓘ	20	25	38	44	41	55	53	60	78	94
Operating Profit Margin (%)	7.5%	7.9%	12.0%	15.4%	12.6%	12.8%	11.4%	11.7%	12.4%	12.4%
Other Income ⓘ +	1	4	3	2	2	3	7	10	13	18
Exceptional Items ⓘ	0	0	0	0	0	-32	0	0	0	0
Interest ⓘ	7	5	5	4	3	1	1	1	1	4
Depreciation ⓘ	9	9	11	8	9	13	12	12	13	28
Profit Before Tax ⓘ	6	14	25	35	32	11	46	57	77	79
Tax ⓘ	1	5	8	12	8	6	7	14	19	19
Profit After Tax	5	9	17	22	24	5	39	43	58	61
PAT Margin (%)	1.7%	2.9%	5.3%	7.8%	7.2%	1.2%	8.3%	8.3%	9.2%	8.0%
Adjusted EPS (₹)	2.9	5.8	10.7	12.3	13.0	2.8	17.7	20.4	28.0	28.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	19.80%	19.60%	19.70%	20%

Valuation of Windlas Biotech - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	141	150	167	194	220	199	393	400	445	501
Share Capital ⓘ	9	9	9	6	6	6	11	10	10	10
Reserves ⓘ	132	141	158	188	214	193	382	389	435	490
Debt +	44	51	30	23	22	30	6	0	0	27
Long Term Debt	20	18	12	6	1	1	0	0	0	0
Short Term Debt	24	33	18	17	21	29	5	0	0	27
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	76	77	75	58	83	40	63	87	131	167
Others Liabilities ⓘ	20	25	25	20	23	27	27	40	49	65
Total Liabilities ⓘ	280	303	297	295	349	296	489	527	626	760
Fixed Assets
Net Fixed Assets ⓘ +	56	56	58	62	70	96	91	109	179	223
Gross Block	91	101	114	126	79	184	164	194	275	347
Accumulated Depreciation	35	45	56	64	9	88	73	85	96	123
CWIP ⓘ	9	15	11	5	0	0	8	15	6	5
Investments ⓘ	95	121	123	121	127	23	65	107	173	223
Inventories	27	40	27	19	49	41	59	75	62	81
Trade Receivables	55	61	59	62	64	79	111	117	136	167
Cash Equivalents	29	2	6	13	18	31	114	25	31	16
Others Assets ⓘ	9	8	13	13	20	25	42	79	38	44
Total Assets ⓘ	280	303	297	295	349	296	489	527	626	760

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	47	7	39	22	25	11	9	61	109	68
PBT ⓘ	6	14	25	35	32	11	46	57	77	79
Adjustment ⓘ	16	12	15	10	10	47	10	7	7	18
Changes in Working Capital ⓘ	29	-18	4	-9	-4	-40	-38	6	44	-9
Tax Paid ⓘ	-3	-2	-5	-13	-13	-7	-9	-10	-19	-21
Cash Flow From Investing Activity ⓘ +	-62	-39	-11	-7	-14	-20	-154	-14	-92	-74
Capex	-13	-15	-11	-10	-15	-6	-15	-70	-38	-52
Net Investments	0	0	-0	3	0	87	-142	51	-56	-24
Others ⓘ	-49	-23	1	1	1	-102	3	5	2	2
Cash Flow From Financing Activity ⓘ +	39	5	-25	-8	-5	1	130	-44	-15	1
Net Proceeds from Shares ⓘ	1	0	0	5	0	0	165	0	0	4
Net Proceeds from Borrowing ⓘ	0	0	-5	-8	-6	-5	-0	-0	-0	0
Interest Paid ⓘ	-7	-5	-5	-3	-3	-1	-1	-1	-1	-4
Dividend Paid ⓘ	0	0	0	0	0	0	0	-8	-8	-11
Others ⓘ	45	10	-15	-1	3	7	-33	-35	-6	12
Net Cash Flow ⓘ	24	-27	4	7	5	-8	-15	3	2	-5

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	4.51	6.44	10.88	12.56	11.43	2.39	13.02	10.75	13.76	12.82
ROCE (%)	7.68	9.55	14.37	17.9	14.7	5.22	15.03	14.38	18.31	17.04
Asset Turnover Ratio	1.14	1.08	1.07	0.97	1.02	1.33	1.19	1.01	1.09	1.1
PAT to CFO Conversion(x)	9.4	0.78	2.29	1	1.04	2.2	0.23	1.42	1.88	1.11
Working Capital Days
Receivable Days	82.10	67	68.40	77.10	70	61.20	74.50	81	73.20	72.80
Inventory Days	39.60	38.70	37.80	28.80	37.90	38.70	39.20	47.50	39.60	34.50
Payable Days	116.50	119.10	123.60	133.90	121.70	85.90	64.60	91.80	106.50	120

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Windlas Biotech Ltd FAQs

The current trading price of Windlas Biotech on 24-Jun-2026 16:59 is ₹863.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jun-2026 the market cap of Windlas Biotech stood at ₹1,782.1 Cr

The latest P/E ratio of Windlas Biotech as of 23-Jun-2026 is 26.83.

The latest P/B ratio of Windlas Biotech as of 23-Jun-2026 is 3.34.

The 52-week high of Windlas Biotech is ₹1,095 and the 52-week low is ₹699.4.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Windlas Biotech is ₹904 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Windlas Biotech Ltd is a good quality company.

The key valuation ratios of Windlas Biotech Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Windlas Biotech Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Windlas Biotech Ltd

Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, it provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to providing services and products in the CDMO market, it also sell its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company’s CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end users. The company’s Domestic Trade Generics and OTC Brands SBV consists of (i) trade generic products; and (ii) OTC brands, which include nutraceutical and health supplement products that do not require prescription and are marketed, distributed and promoted in India under its own brand names through online and offline channels and majorly manufactured by it. Trade generic products are generic medicines, i.e. drugs for which the patents have expired, which are sold directly to the distributor and not marketed through medical representatives, and are typically used as a substitute for more expensive branded generic medicines in order to offer affordable medicines to patients by the retailers and pharmacies. The company’s Exports SBV is engaged in identifying high growth markets and opportunities in semi-regulated international markets as well as selected regulated markets, for developing and registering product applications to obtain marketing authorizations for generic medicines and health supplements and subsequently, sell such products to pharmaceutical companies and pharmacies in the respective markets.

Business area of the company

The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Awards, accreditations and recognitions

2018: The company was awarded the TV100 Industrial Excellence Award in the field of medicine.
2019: The company was awarded the certificate of appreciation from the Secretary, Bureau of Energy Efficiency for valuable contributions in implementing energy efficiency and cleaner production measures under the project ‘Financing Energy Efficiency at MSMEs’.
2019: The company was awarded the certificate of partnership recognizing its contribution to and participation in the Swasth Bharat Yatra, a pan-India cyclothon organised by the Food Safety and Standards Authority of India.

Major events and milestones

2001: Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production.
2009: Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110.
2010: Revenues crossed Rs 1,000 million for the FY 2009-10.
2014: Received first USFDA inspection clearance for the WHC Plant.
2014: Revenues crossed Rs 2,000 million for the FY 2013-14.
2014: Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 110.
2015: Investment of Rs 750 million from Tano India Private Equity Fund II.
2017: Revenues crossed Rs 3,000 million for the FY 2016-17.
2018: Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun.
2018: Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun.
2021: Approval of Scheme of Amalgamation of its erstwhile subsidiary, Windlas Healthcare, with and into the company.

Windlas Biotech Ltd (WINDLAS)

Windlas Biotech Ltd (WINDLAS)

Windlas Biotech stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Windlas Biotech - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Windlas Biotech Ltd FAQs

About Windlas Biotech Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Windlas Biotech Ltd (WINDLAS)

Windlas Biotech Ltd (WINDLAS)

Windlas Biotech stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Windlas Biotech - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Windlas Biotech Ltd FAQs

What is the share price of Windlas Biotech?

What is the market cap of Windlas Biotech?

What is the P/E ratio of Windlas Biotech?

What is the P/B ratio of Windlas Biotech?

What is the 52-week high and low of Windlas Biotech?

What is the TTM revenue of Windlas Biotech?

Is Windlas Biotech Ltd a good quality company?

Is Windlas Biotech Ltd undervalued or overvalued?

Is Windlas Biotech Ltd a good buy now?

About Windlas Biotech Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.